7.7 C
London
Friday, February 28, 2025
Subscribe
Home Tags Eisai’s

Tag: Eisai’s

Japan – Eisai’s “URECE(R)” (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
Business

Japan – Eisai’s “URECE(R)” (Dotinurad) Approved in China for Gout Patients with Hyperuricemia

Leslie Atkins -
0
Japan – Eisai’s Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED’s ‘Strengthening Program for Pharmaceutical Startup Ecosystem”
Business

Japan – Eisai’s Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED’s ‘Strengthening Program for Pharmaceutical Startup Ecosystem”

Editor -
0
Japan – Eisai’s Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures
Business

Japan – Eisai’s Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures

-
0
Japan – Eisai’s Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
Business

Japan – Eisai’s Antiepileptic Drug Fycompa Injection Formulation Launched In Japan

-
0
Japan – Eisai’s Sales Subsidiary Collaborates with Ministry of Public Health (MOPH) in Thailand
Business

Japan – Eisai’s Sales Subsidiary Collaborates with Ministry of Public Health (MOPH) in Thailand

-
0
Japan – Eisai’s Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria and Commitment for Funding to the 3rd Phase of Global Health Innovative Technology Fund Activities
Business

Japan – Eisai’s Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria and Commitment for Funding to the 3rd Phase of Global Health Innovative Technology Fund Activities

-
0
Japan – FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
Business

Japan – FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

Editor -
0
Japan – Eisai’s Sales Subsidiary Collaborates with Thai Life Insurance to Support Access to Treatments for Dementia, Including Alzheimer’s Disease, in Thailand
Business

Japan – Eisai’s Sales Subsidiary Collaborates with Thai Life Insurance to Support Access to Treatments for Dementia, Including Alzheimer’s Disease, in Thailand

Editor -
0
Japan – Eisai’s Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint
Business

Japan – Eisai’s Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint

-
0
Eisai’s Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study
Business

Eisai’s Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study

-
0
Eisai’s Statement of Commitment for Carbon Neutrality by 2040
Uncategorized

Eisai’s Statement of Commitment for Carbon Neutrality by 2040

-
0
© Newspaper WordPress Theme by TagDiv